WASHINGTON — The U.S. Food and Drug Administration is preparing for another major leadership change, with the federal health establishment considering new deputy commissioner positions that would divide responsibility for drugs and emerging technologies, including artificial intelligence.
The proposed structure comes as the FDA works through a period of unusually high turnover and policy uncertainty. The agency is currently led by Acting Commissioner Kyle Diamantas, while the position of principal deputy commissioner remains vacant, according to the FDA’s leadership directory.
Now, the Department of Health and Human Services is reportedly considering two new deputy commissioner roles—one focused on drugs and another covering technology sectors such as healthcare technology and AI.
The changes could reshape how the FDA manages some of the most consequential areas of modern healthcare.
A New Structure for a Changing FDA
The reported proposal reflects the growing complexity of the FDA’s responsibilities.
Traditional drug regulation remains at the center of the agency’s mission, but healthcare technology has expanded rapidly. Artificial intelligence, digital health platforms, software-based medical tools and technology-assisted clinical research are creating regulatory questions that did not exist at the same scale a decade ago.
Under the reported plan, a technology-focused deputy commissioner would oversee areas including healthcare technology and artificial intelligence, while another deputy would concentrate on drug responsibilities.
No final appointments had been formally announced at the time of the reports.
Leadership Turnover Has Created Uncertainty
The restructuring comes after significant changes at the top of the agency.
Former FDA Commissioner Marty Makary resigned in May after roughly 13 months in the position. His departure followed disagreements with the White House over several policy issues, according to Reuters.
The leadership disruption has extended beyond the commissioner’s office.
The agency has also experienced changes involving the leaders of its major product-review centers, including the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
For pharmaceutical companies, the concern is not necessarily that regulatory decisions will stop. Rather, repeated leadership changes can create uncertainty about priorities, communication and the direction of future policy.
Drug Regulation Remains the FDA’s Core Mission
The FDA’s Center for Drug Evaluation and Research plays a central role in determining whether new medicines can be marketed in the United States.
The agency evaluates evidence submitted by drug developers to determine whether a product’s benefits outweigh its known risks. The review process involves physicians, statisticians, chemists, pharmacologists and other scientific experts.
That responsibility makes leadership at the drug division particularly important for the pharmaceutical industry.
Companies developing medicines can spend years and billions of dollars moving a therapy through laboratory research and clinical trials.
Regulatory decisions can determine whether those investments ultimately reach patients.
AI Creates a New Regulatory Challenge
At the same time, artificial intelligence is changing the healthcare landscape.
AI can be used to analyze medical images, identify patterns in patient data, assist clinical decision-making and support drug-development research.
But regulators must also determine how these systems should be evaluated when algorithms change over time or produce outputs that are difficult to explain.
The FDA has already been developing frameworks for digital health technologies used in drug development.
The agency says its work includes establishing a Digital Health Technologies Steering Committee, developing a framework for digital technologies and conducting demonstration projects.
A dedicated technology leadership position could therefore give these issues a more prominent place inside the agency.
Digital Health Is Moving Into Drug Development
The intersection between technology and drug development is becoming increasingly important.
Digital tools can generate data from wearable devices, remote monitoring systems and decentralized clinical trials.
Those data can potentially help researchers measure treatment outcomes outside traditional clinical settings.
The FDA has scheduled workshops to examine statistical considerations surrounding digitally derived endpoints in clinical trials, demonstrating the agency’s growing focus on technology-enabled research.
The challenge is ensuring that new technology produces reliable evidence that regulators can use when making decisions about medical products.
The Industry Is Watching Closely
Pharmaceutical and biotechnology companies have a direct interest in how the FDA’s new structure develops.
Drugmakers want predictable regulatory processes, clear communication and timely decisions.
Technology companies, meanwhile, increasingly need to understand where their products fall within the healthcare regulatory system.
A dedicated technology leader could potentially provide greater clarity for companies developing AI-powered medical products.
But the effectiveness of the new structure will depend on the authority given to those positions and how responsibilities are divided among existing FDA centers.
The Agency Is Already Under Pressure
The leadership restructuring comes at a challenging time for the FDA.
The agency is dealing with questions involving drug approvals, vaccines, tobacco and nicotine products, medical devices, biotechnology and emerging technologies.
It is also facing broader political pressure over how federal health agencies should operate.
The result is an FDA that must manage traditional regulatory responsibilities while simultaneously responding to rapid technological change.
Drug Approvals Continue Despite the Turmoil
The leadership changes have not stopped the FDA from making regulatory decisions.
In late August, the agency approved Mimrylo (rusfertide), developed by Takeda Pharmaceutical and Protagonist Therapeutics, for adults with polycythemia vera, a rare blood cancer. Reuters reported that the approval represents a new treatment option that can reduce patients’ reliance on therapeutic blood removal.
The approval illustrates an important point: despite leadership turnover, the agency’s scientific and regulatory machinery continues operating.
The bigger question is whether the organizational changes will influence the speed, priorities and consistency of future decisions.
Technology Oversight Could Become More Important
The proposed technology role could become one of the most closely watched positions inside the FDA.
AI is moving rapidly into healthcare, while regulators generally operate through processes designed around products that can be evaluated using established scientific frameworks.
Technology can evolve much faster.
An AI system may receive software updates, be trained on new data or behave differently when deployed in a new environment.
That raises questions about how regulators should monitor products after they enter the market.
Balancing Innovation and Patient Safety
The FDA’s challenge is not simply to approve innovative products faster.
It must balance innovation with patient safety.
A regulatory system that moves too slowly could discourage investment and delay potentially beneficial technologies.
A system that moves too quickly could allow products onto the market before regulators have enough evidence about their safety or effectiveness.
That tension is likely to become even more important as AI becomes more deeply integrated into medical care.
A Potential Shift in Regulatory Priorities
The creation of separate leadership responsibilities for drugs and technology could signal a broader recognition inside Washington that healthcare technology requires specialized regulatory attention.
The FDA’s existing structure already includes multiple centers and specialized offices.
The agency’s official organization charts show a complex system designed to oversee different categories of medical products and public-health responsibilities.
Adding senior leadership specifically focused on technology could create another layer of coordination.
Questions Remain About the Final Structure
The reported changes are not yet the final word on the FDA’s organization.
The agency and HHS have not formally announced all of the proposed appointments.
Reports have identified potential candidates and responsibilities, but the final structure could change before implementation.
That means the pharmaceutical and technology industries are watching both the leadership process and the policy decisions that follow.
What It Means for Americans
For patients, changes inside the FDA may appear distant from everyday healthcare.
But the agency’s decisions influence which prescription drugs, vaccines, medical devices and other products can reach the U.S. market.
Its regulatory decisions can also affect how quickly new technologies become available to doctors and patients.
As AI becomes increasingly common in healthcare, the agency’s approach to technology could have an especially visible impact.
The Bigger Washington Debate
The restructuring is also part of a larger debate over the role of federal health agencies.
Supporters of organizational changes argue that government agencies need to become more efficient and adapt to new technology.
Critics worry that excessive turnover or political interference could weaken institutional expertise and regulatory consistency.
Those competing arguments are likely to remain central as the FDA moves toward its next leadership phase.
The Bottom Line
The FDA is preparing for another potential transformation as Washington considers separate senior leadership roles for drug regulation and emerging technologies, including artificial intelligence.
The reported plan would create a deputy commissioner focused on technology and another responsible for drug-related oversight.
The proposal comes after a period of significant leadership turnover that has left the FDA operating under an acting commissioner and without a permanent principal deputy commissioner.
For pharmaceutical companies, stability and regulatory clarity will remain major concerns.
For technology companies, the creation of a dedicated AI and healthcare technology leadership role could provide a clearer regulatory pathway as digital health expands.
And for patients, the ultimate test will be whether the new structure can encourage innovation without compromising the FDA’s fundamental responsibility to protect public health.
Washington is now attempting to redesign the leadership of one of America’s most powerful health agencies at the same time that medicine itself is being transformed by artificial intelligence and digital technology. How that balance is managed could shape the next era of U.S. drug and healthcare regulation.
Source angle: FDA leadership records, Reuters reporting on proposed deputy commissioner roles, FDA drug-review procedures and the agency’s digital-health technology initiatives.